Dogwood to Showcase Halneuron® Data in Virtual KOL Event Amid Phase 2b Trial
Event summary
- Dogwood Therapeutics will host a virtual KOL event on September 1, 2026, to discuss Halneuron® for treating chemotherapy-induced neuropathic pain (CINP).
- The event will feature experts including J. Mark Joyce, M.D., Iain D. Dukes, D.Phil., and Jerry Evarts, Ph.D., alongside Dogwood management.
- Halneuron® has been tested on over 800 patients, with ongoing Phase 2b trial (HAL-CINP) evaluating its efficacy in 210–240 patients with CINP.
- The trial aims to assess pain reduction, sleep, fatigue, and neuropathy symptoms over a 28-day follow-up period.
The big picture
Dogwood Therapeutics is positioning Halneuron® as a non-opioid alternative for treating CINP, a condition with significant unmet medical needs. The KOL event underscores the strategic importance of differentiating Halneuron® through its unique mechanism of action and ongoing clinical data. The broader industry trend toward non-opioid pain management solutions highlights the potential market opportunity for Dogwood's lead candidate.
What we're watching
- Clinical Trial Progress
- The pace at which Dogwood reports interim results from the Phase 2b trial will signal Halneuron®'s potential efficacy and safety profile.
- Regulatory Pathway
- Whether the FDA's fast track designation for Halneuron® accelerates its approval process for CINP treatment.
- Market Differentiation
- How Halneuron®'s selective NaV 1.7 mechanism of action positions it against existing and future NaV inhibitors in the pain management market.